What Predicts Early Fracture or Bone Loss on Bisphosphonate Therapy?

Journal of Clinical Densitometry

Volumn 6, Issue 4, 2003, Pages 315-322

  Sawka, Anna M ^a,b   Adachi, Jonathan D ^a,b,h   Ioannidis, George ^b   Olszynski, Wojciech P ^c   Brown, Jacques P ^d   Hanley, David A ^e   Murray, Tim ^f   Josse, Robert ^f   Sebaldt, Rolf J ^a,b   Petrie, Annie ^a,b   Tenenhouse, Alan ^g   Papaioannou, Alexandra ^b   Goldsmith, Charlie H ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h NONE   (Canada)

Author keywords

Alendronate; Bisphosphonate; Bone density; Etidronate; Fracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID;

AGED; ARTICLE; BONE MASS; CONFIDENCE INTERVAL; FEMALE; FRACTURE; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; SPINE; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 9144250181     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1385/JCD:6:4:315     Document Type: Article

References (24)

1. Harris ST. 2001 Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate. Osteoporos Int 3(suppl):S11-S16.
2. Watts NB. 1998 Treatment of osteoporosis with bisphosphonates. Endocrin Metab Clin 27:419-439.
3. Crilly RG, Sebaldt RJ, Hodsman AB, et al. 2000 Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial response in patients with osteoporosis. Osteoporos Int 11:607-614.
4. Cranney A, Guyatt G, Welch V, et al. 2001 A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 12:140-151.
5. Sahota O, Fowlser I, Blackwell PJ, et al. 2000 A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial. Osteoporos Int 11:959-966.
6. Gatti D, Adami S. 1999 New bisphosphonates in the treatment of bone diseases. Drug Aging 15:285-296.
7. Seeman E. 1997 Osteoporosis: trials and tribulations. Am J Med 103:74S-89S.
8. Cummings SR, Karpf DB, Harris F, et al. 2002 Improvement in spine bone density and reduction in vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
9. Hochberg MC, Ross PD, Black D, et al., Group. 1999 Larger increases in bone mineral density with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:1246-1254.
10. Ensrud KE, Black DM, Palermo L, et al. 1997 Treatment with alendronate prevents fractures in women at highest risk: results of the Fracture Intervention Trial. Arch Intern Med 157:2617-2624.
11. Black DM, Cummings SR, Karpf DB, et al. 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
12. Cummings SR, Black DM, Thompson DE, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results of the Fracture Intervention Trial. JAMA 280:2077-2082.
13. McClung M, Clemmesen B, Daifotis A, et al. 1998 Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med 128:253-261.
14. Black DM, Thompson DE, Bauer DC, et al. 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol 85:4118-4124.
15. De Growen PC, Lubbe DF, Hirsch LJ, et al. 1996 Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021.
16. Bauer DC, Black D, Ensrud K, et al. 2000 Upper gastrointestinal tract safety profile of alendronate: The Fracture Intervention Trial. Arch Intern Med 160:517-525.
17. Devogelaer JP. 1998 A risk-benefit assessment of alendronate in the treatment of involutinal osteoporosis. Drug Safety 19:141-154.
18. Ontario Program for Optimal Therapeutics. 2000 Ontario Guidelines for the Prevention and Treatment of Osteoporosis. Queen's Printer of Ontario, 37.
19. Ontario Ministry of Health and Long-Term Care. 2001 Drug Benefit Formulary/Comparative Drug Index 2001. Queen's Printer of Ontario; 1996 Edition 37:XII.19.
20. Watts NB, Becker P. 1999 Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to responds to cyclic etidronate therapy. Bone 24:65-68.
21. Fairney A, Kyd P, Thomas E, Wilson J. 2000 Response to alendronate in osteoporosis after treatment with etidronate Osteoporos Int 11:621-625.
22. Cummings SR, Palermo L, Browner W, et al. 2000 Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 283:1318-1321.
23. Ross PD. 1998 Risk factors for osteoporotic fracture. Endocrin Metab Clin 27:289-301.
24. Nevitt MC, Ross PD, Palermo L, Musliner T, Genant HK, Thompson DE, for the Fracture Intervention Trial Research Group. 1999 Association of prevalent vertebral fractures, bone density, and alendronate with incident vertebral fractures: effect of number and spinal location of fractures. Bone 25:613-619.